NCT05816057 is a Phase 3 clinical trial of semaglutide injection in Diabetes Mellitus, Type 2, sponsored by Hangzhou Jiuyuan Gene Engineering Co. Ltd.,.

Who is sponsoring NCT05816057?

NCT05816057 is sponsored by Hangzhou Jiuyuan Gene Engineering Co. Ltd.,.

What drugs are being tested in NCT05816057?

Interventions in NCT05816057: semaglutide injection.

What condition does NCT05816057 study?

NCT05816057 studies Diabetes Mellitus, Type 2.

Is NCT05816057 still recruiting?

NCT05816057 is currently completed. Last updated 3 January 2024.

Last reviewed 2024-01-03 · How we verify

NCT05816057

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus

Completed Phase 3 Last updated 3 January 2024

What this trial tests

Phase 3 trial testing semaglutide injection in Diabetes Mellitus, Type 2 in 476 participants. Completed in 31 October 2023.

Timeline

25 July 2022

Primary endpoint
25 July 2023

31 October 2023

Quick facts

Lead sponsor	Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	476
Start date	25 July 2022
Primary completion	25 July 2023
Estimated completion	31 October 2023
Sites	35 locations across China

Drugs / interventions tested

semaglutide injection

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Hangzhou Jiuyuan Gene Engineering Co. Ltd., — full company profile →

Who can join

Adults 18 to 75, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Semaglutide injection is a new drug developed according to Ozempic® biosimilars.This trial is conducted in China. The purpose of this study is to investigate the similarities in the efficacy and safety of semaglutide injection and Ozempic® in the treatment of type 2 diabetes, respectively.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

RepurposeDrugs: an interactive web-portal and predictive platform for repurposing mono- and combination therapies.
Ianevski A, Kushnir A, Nader K, Miihkinen M, et al · · 2024 · cited 15× · PMID 38980370 · DOI 10.1093/bib/bbae328

Verify or expand the search:

Other trials of semaglutide injection

Trials testing the same drug.

NCT07073417 — A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH) · Phase 2 · active not recruiting
NCT06577090 — Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo · Phase 2 · active not recruiting

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Hangzhou Jiuyuan Gene Engineering Co. Ltd., trials

Trials by the same sponsor.

NCT06633783 — A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy® · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05816057 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Last refreshed: 3 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05816057.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing